Clinical grade adult stem cell banking

Sreedhar Thirumala, W. Goebel, Erik J. Woods

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

There has been a great deal of scientific interest recently generated by the potential therapeutic applications of adult stem cells in human care but there are several challenges regarding quality and safety in clinical applications and a number of these challenges relate to the processing and banking of these cells ex-vivo. As the number of clinical trials and the variety of adult cells used in regenerative therapy increases, safety remains a primary concern. This has inspired many nations to formulate guidelines and standards for the quality of stem cell collection, processing, testing, banking, packaging and distribution. Clinically applicable cryopreservation and banking of adult stem cells offers unique opportunities to advance the potential uses and widespread implementation of these cells in clinical applications. Most current cryopreservation protocols include animal serum proteins and potentially toxic cryoprotectant additives (CPAs) that prevent direct use of these cells in human therapeutic applications. Long term cryopreservation of adult stem cells under good manufacturing conditions using animal product free solutions is critical to the widespread clinical implementation of ex-vivo adult stem cell therapies. Furthermore, to avoid any potential cryoprotectant related complications, reduced CPA concentrations and efficient post-thaw washing to remove CPA are also desirable. The present review focuses on the current strategies and important aspects of adult stem cell banking for clinical applications. These include current good manufacturing practices (cGMPs), animal protein free freezing solutions, cryoprotectants, freezing & thawing protocols, viability assays, packaging and distribution. The importance and benefits of banking clinical grade adult stem cells are also discussed.

Original languageEnglish
Pages (from-to)143-154
Number of pages12
JournalOrganogenesis
Volume5
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Adult Stem Cells
Stem cells
Cryopreservation
Product Packaging
Animals
Freezing
Packaging
Safety
Proteins
Poisons
Cell- and Tissue-Based Therapy
Thawing
Processing
Blood Proteins
Washing
Stem Cells
Therapeutics
Assays
Clinical Trials
Guidelines

Keywords

  • Adipose derived stem cells
  • Clinical banking
  • Cryopreservation
  • Current good manufacturing practice
  • Dental pulp derived stem cells
  • Mesenchymal stem cells
  • Placenta derived stem cells

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Transplantation
  • Biomedical Engineering

Cite this

Clinical grade adult stem cell banking. / Thirumala, Sreedhar; Goebel, W.; Woods, Erik J.

In: Organogenesis, Vol. 5, No. 3, 2009, p. 143-154.

Research output: Contribution to journalArticle

Thirumala, Sreedhar ; Goebel, W. ; Woods, Erik J. / Clinical grade adult stem cell banking. In: Organogenesis. 2009 ; Vol. 5, No. 3. pp. 143-154.
@article{d7226e54ed544efa8b73d00fd39cdd1a,
title = "Clinical grade adult stem cell banking",
abstract = "There has been a great deal of scientific interest recently generated by the potential therapeutic applications of adult stem cells in human care but there are several challenges regarding quality and safety in clinical applications and a number of these challenges relate to the processing and banking of these cells ex-vivo. As the number of clinical trials and the variety of adult cells used in regenerative therapy increases, safety remains a primary concern. This has inspired many nations to formulate guidelines and standards for the quality of stem cell collection, processing, testing, banking, packaging and distribution. Clinically applicable cryopreservation and banking of adult stem cells offers unique opportunities to advance the potential uses and widespread implementation of these cells in clinical applications. Most current cryopreservation protocols include animal serum proteins and potentially toxic cryoprotectant additives (CPAs) that prevent direct use of these cells in human therapeutic applications. Long term cryopreservation of adult stem cells under good manufacturing conditions using animal product free solutions is critical to the widespread clinical implementation of ex-vivo adult stem cell therapies. Furthermore, to avoid any potential cryoprotectant related complications, reduced CPA concentrations and efficient post-thaw washing to remove CPA are also desirable. The present review focuses on the current strategies and important aspects of adult stem cell banking for clinical applications. These include current good manufacturing practices (cGMPs), animal protein free freezing solutions, cryoprotectants, freezing & thawing protocols, viability assays, packaging and distribution. The importance and benefits of banking clinical grade adult stem cells are also discussed.",
keywords = "Adipose derived stem cells, Clinical banking, Cryopreservation, Current good manufacturing practice, Dental pulp derived stem cells, Mesenchymal stem cells, Placenta derived stem cells",
author = "Sreedhar Thirumala and W. Goebel and Woods, {Erik J.}",
year = "2009",
doi = "10.4161/org.5.3.9811",
language = "English",
volume = "5",
pages = "143--154",
journal = "Organogenesis",
issn = "1547-6278",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Clinical grade adult stem cell banking

AU - Thirumala, Sreedhar

AU - Goebel, W.

AU - Woods, Erik J.

PY - 2009

Y1 - 2009

N2 - There has been a great deal of scientific interest recently generated by the potential therapeutic applications of adult stem cells in human care but there are several challenges regarding quality and safety in clinical applications and a number of these challenges relate to the processing and banking of these cells ex-vivo. As the number of clinical trials and the variety of adult cells used in regenerative therapy increases, safety remains a primary concern. This has inspired many nations to formulate guidelines and standards for the quality of stem cell collection, processing, testing, banking, packaging and distribution. Clinically applicable cryopreservation and banking of adult stem cells offers unique opportunities to advance the potential uses and widespread implementation of these cells in clinical applications. Most current cryopreservation protocols include animal serum proteins and potentially toxic cryoprotectant additives (CPAs) that prevent direct use of these cells in human therapeutic applications. Long term cryopreservation of adult stem cells under good manufacturing conditions using animal product free solutions is critical to the widespread clinical implementation of ex-vivo adult stem cell therapies. Furthermore, to avoid any potential cryoprotectant related complications, reduced CPA concentrations and efficient post-thaw washing to remove CPA are also desirable. The present review focuses on the current strategies and important aspects of adult stem cell banking for clinical applications. These include current good manufacturing practices (cGMPs), animal protein free freezing solutions, cryoprotectants, freezing & thawing protocols, viability assays, packaging and distribution. The importance and benefits of banking clinical grade adult stem cells are also discussed.

AB - There has been a great deal of scientific interest recently generated by the potential therapeutic applications of adult stem cells in human care but there are several challenges regarding quality and safety in clinical applications and a number of these challenges relate to the processing and banking of these cells ex-vivo. As the number of clinical trials and the variety of adult cells used in regenerative therapy increases, safety remains a primary concern. This has inspired many nations to formulate guidelines and standards for the quality of stem cell collection, processing, testing, banking, packaging and distribution. Clinically applicable cryopreservation and banking of adult stem cells offers unique opportunities to advance the potential uses and widespread implementation of these cells in clinical applications. Most current cryopreservation protocols include animal serum proteins and potentially toxic cryoprotectant additives (CPAs) that prevent direct use of these cells in human therapeutic applications. Long term cryopreservation of adult stem cells under good manufacturing conditions using animal product free solutions is critical to the widespread clinical implementation of ex-vivo adult stem cell therapies. Furthermore, to avoid any potential cryoprotectant related complications, reduced CPA concentrations and efficient post-thaw washing to remove CPA are also desirable. The present review focuses on the current strategies and important aspects of adult stem cell banking for clinical applications. These include current good manufacturing practices (cGMPs), animal protein free freezing solutions, cryoprotectants, freezing & thawing protocols, viability assays, packaging and distribution. The importance and benefits of banking clinical grade adult stem cells are also discussed.

KW - Adipose derived stem cells

KW - Clinical banking

KW - Cryopreservation

KW - Current good manufacturing practice

KW - Dental pulp derived stem cells

KW - Mesenchymal stem cells

KW - Placenta derived stem cells

UR - http://www.scopus.com/inward/record.url?scp=70349771950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349771950&partnerID=8YFLogxK

U2 - 10.4161/org.5.3.9811

DO - 10.4161/org.5.3.9811

M3 - Article

VL - 5

SP - 143

EP - 154

JO - Organogenesis

JF - Organogenesis

SN - 1547-6278

IS - 3

ER -